



October 29, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

Symbol: STAR

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Press Release

Please find enclosed herewith Press Release issued by the Company titled:

**“Strides Delivers Strong Performance with Q2FY27 Revenue at ₹14,297m, Grew 17% YoY
Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m
in a Quarter for the First Time”**

Board Meeting for considering the unaudited financial results for the quarter and half year ended September 30, 2026 commenced at 16:45 hrs (IST) and concluded at 18:15 hrs (IST).

The above information shall be made available on the website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited**,

MANJULA
RAMAMURTHY

Digitally signed by
MANJULA RAMAMURTHY
Date: 2026.10.29 18:33:45
+05'30'

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199
corpcomm@strides.com; www.strides.com

Strides Delivers Strong Performance with Q2FY27 Revenue at ₹14,297m, Grew 17% YoY

Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m in a Quarter for the First Time

Q2FY27 Performance Highlights

- **Revenue up 17.1% YoY to ₹14,297m**, led by strong 31% YoY growth in the Ex-US Markets
- **US business at ₹6,855m (\$73m)**, up 9% YoY; 3 products launched during the quarter
- **Ex-US Markets revenue at ₹6,963m (\$74m)**, up 31% YoY, surpassing the US business in quarterly revenue for the first time
- **EBITDA up 8.4% YoY to ₹2,509m**, crossing the ₹2,500m mark in a quarter for the first time despite higher input material and freight costs; EBITDA margin at 17.6%
- **Operational PAT up 11.5% YoY to ₹1,358m**; Operational EPS at ₹14.7
- **Reported PAT up 2.0% YoY to ₹1,341m**; Reported EPS at ₹14.2

Bangalore, India, 29 October 2026 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q2FY27) and half year (H1FY27) ended 30 September, 2026.

Financial Highlights (In ₹m)

Particulars (₹m)	Q2FY27	Q2FY26	YoY	Q1FY27	QoQ	H1FY27	H1FY26	YoY
Revenue	14,297	12,208	17.1%	12,654	13.0%	26,951	23,406	15.1%
Gross Margin	8,003	7,056	13.4%	7,702	3.9%	15,705	13,810	13.7%
Gross Margin %	56.0%	57.8%	-180 bps	60.9%	-490 bps	58.3%	59.0%	-70 bps
EBITDA	2,509	2,316	8.4%	2,298	9.2%	4,807	4,496	6.9%
EBITDA %	17.6%	19.0%	-140 bps	18.2%	-60 bps	17.8%	19.2%	-140 bps
Operational PAT	1,358	1,218*	11.5%	1,231	10.3%	2,589	2,358*	9.8%
Operational EPS (₹)	14.7	13.2	11.6%	13.4	10.3%	28.1	25.6	9.9%
Reported PAT	1,341	1,315	2.0%	1,655	-19.0%	2,996	2,371	26.4%
Reported EPS (₹)	14.2	13.8	2.6%	17.0	-16.6%	31.2	24.6	26.7%

*Q2FY26 and H1FY26 Operational PAT and Operational EPS exclude one-time finance income of ₹185m; Operational PAT = Reported PAT excluding exceptional items

Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides delivered a strong second quarter, with revenue of ₹14,297m growing ~17% YoY, driven by Ex-US Markets. Our diversification strategy continues to play out, with Ex-US Markets growing 31% YoY to ₹6,963m and, for the first time, surpassing our US business in quarterly revenue. Our US business delivered 9% YoY growth. EBITDA grew to ₹2,509m, crossing the ₹2,500m mark in a quarter for the first time. This was despite higher raw material, freight and operating costs arising from geopolitical disruptions. We remain focused on mitigating these pressures through continuous cost optimization initiatives during the year. Net Debt increased by ₹2,114m during H1 due to an elongated cash-to-cash cycle and higher inventory holding to navigate current market conditions. We expect the Net Debt to EBITDA ratio to stabilize by the end of the year. We are also pleased to welcome Mr. Biren Gabhawala to our Board as an Independent Director. His deep expertise in financial reporting, audit and corporate governance will further strengthen the Board’s oversight. While the external environment remains dynamic, we are committed to

delivering sustainable and profitable growth.”

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For further information, please contact:

Investor Relations Vikesh Kumar: Group CFO investor-relations@strides.com Saurabh Ambaselkar: +91 99609 31220 saurabh.ambaselkar@strides.com Strides Pharma Science Limited Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076	Corporate Communication Pallavi Panchmatia: +91 80 6784 0193 Pallavi.panchmatia@strides.com Abhilash Mukherjee: +91 89044 28907 Abhilash.Mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 adrita.chatterjee@adfactorspr.com
---	---